Jubilant Pharmova Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,370 Cr +20.5% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
JP

Jubilant Pharmova Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Jubilant Pharmova Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹2,122Cr
+16.5% YoY
+7.9% QoQ
Net profit
₹56Cr
−44.6% YoY
−53.3% QoQ
Margin
14%
−2 pp YoY
−3 pp QoQ

Based on Jubilant Pharmova Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,064
Market cap₹17.0K Cr
P/E43.7

The short version

Q3’FY26 Total Income: Rs. 2,143 Cr., up from Rs. 1,831 Cr. in Q3’FY25 (approx. 17% YoY growth). Q3’FY26 Financials:.

From Jubilant Pharmova Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

- Q3’FY26 Total Income: Rs. 2,143 Cr., up from Rs. 1,831 Cr. in Q3’FY25 (approx. 17% YoY growth). - Major segments Q3’FY26 revenue with YoY change: • Radiopharma: Rs. 935 Cr. (vs. 841 Cr., ~11% YoY) • Allergy Immunotherapy: Rs. 193 Cr. (vs. 171 Cr., 12% YoY) • CDMO Sterile Injectables: Rs. 457 Cr. (vs. 306 Cr., 49% YoY) • CRDMO: Rs. 298 Cr. (vs. 292 Cr., 2% YoY) • Generics: Rs. 226 Cr. (vs. 200 Cr., 13% YoY) • Drug Discovery Services: Rs. 169 Cr. (vs. 150 Cr., 13% YoY) • CDMO API: Rs. 129 Cr. (vs. 142 Cr., -9% YoY) - Outlook: • Vision 2030 plans to double revenues by FY30 (~2x FY24 revenues).

2 more points from Jubilant Pharmova Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Expansion at Greater Noida & Bengaluru sites; new site Devanahalli, Bengaluru: capacity increasing from 1,000 FTEs (FY25) to 2,000 (FY28) to 4,000 (FY30); Total Capex USD 150 Mn; expected RoCE > 20%.
  • New Isolator Fill & Finish Line (Line 5) at Montreal: construction started; Capex USD 114 Mn, concessional loan USD 35 Mn; production resumed Q4’FY26; technology transfer revenue expected FY29; target EBITDA breakeven FY28.
  • Line 4 installation (Spokane): on track; technology transfer revenue to start Q4’FY27; full utilization in 3.5 years; peak revenue potential USD 80-90 Mn.

2 more points from Jubilant Pharmova Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • On Page 43, the presentation states: "Building a strong order book pipeline" for Line 4 installation.
  • It also mentions expectation of technology transfer revenues to start in Q4’FY27.

Jubilant Pharmova Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Jubilant Pharmova Ltd Q3 FY26 results — key figures

Jubilant Pharmova Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue2,1221,822+16.5%1,966+7.9%
Operating profit (EBITDA)289287+0.7%341-15.2%
Operating margin14%16%-2 pp17%-3 pp
Profit before tax93130-28.5%190-51.1%
Net profit (PAT)56101-44.6%120-53.3%
EPS (₹)3.516.33-44.5%7.55-53.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.4K Cr, net profit ₹31 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Jubilant Pharmova Ltd Q3 FY26 results?

Q3’FY26 Total Income: Rs. 2,143 Cr., up from Rs. 1,831 Cr. in Q3’FY25 (approx. 17% YoY growth). Q3’FY26 Financials:.

What is Jubilant Pharmova Ltd share price analysis?

Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jubilant Pharmova Ltd planning capital expenditure?

Expansion at Greater Noida & Bengaluru sites; new site Devanahalli, Bengaluru: capacity increasing from 1,000 FTEs (FY25) to 2,000 (FY28) to 4,000 (FY30); Total Capex USD 150 Mn; expected RoCE > 20%.

Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.